Isocitrate

Isocitrate

SCHEMBL1289944

O=C(O)CC(C(=O)O)C(O)C(=O)O.O=C(O)CC(C(=O)O)C(O)C(=O)O

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.48
TSHR P16473 2/20 0.47
GABRR1 P24046 2/20 0.40
LMNA P02545 1/20 0.40
CYP2C9 P11712 1/20 0.37
PDE4A P27815 1/20 0.37
FOLH1 Q04609 1/20 0.37
MAPT P10636 1/20 0.36
TET2 Q6N021 3/20 0.35
KDM4A O75164 2/20 0.35
KDM4C Q9H3R0 2/20 0.35
KDM2A Q9Y2K7 2/20 0.35
TET3 O43151 1/20 0.35
CPT2 P23786 1/20 0.34
ACLY P53396 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isocitric Acid SCHEMBL27894954 1.00 TDP1 (0.68) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitric Acid SCHEMBL29645996 1.00 TDP1 (0.68) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitric Acid SCHEMBL30700829 1.00 TDP1 (0.68) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitric Acid SCHEMBL2794437 1.00 TDP1 (0.68) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitric Acid SCHEMBL6249818 1.00 TDP1 (0.68) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitric Acid SCHEMBL12927570 1.00 TDP1 (0.68) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitrate SCHEMBL8373 1.00 TDP1 (0.68) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitrate SCHEMBL23648394 0.97 TDP1 (0.65) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitrate SCHEMBL2580646 0.97 TDP1 (0.74) TDP1SMN1; SMN2SLC22A6TSHRGABRR1
Isocitrate SCHEMBL2396434 0.97 TDP1 (0.65) TDP1SMN1; SMN2SLC22A6TSHRGABRR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689144-A1 CONSOLIDATED BIOPROCESSING OF COMPLEX CARBOHYDRATES TO D-erythro-ISOCITRIC ACID USING A FUNGUS Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut - (DE) 2026-02-11 EP disclosed
US-20260034177-A1 HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) 2026-02-05 US disclosed
WO-2024199940-A1 CONSOLIDATED BIOPROCESSING OF COMPLEX CARBOHYDRATES TO D-erythro-ISOCITRIC ACID USING A FUNGUS LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE – HANS-KNÖLL-INSTITUT – (DE) 2024-10-03 WO disclosed
CN-118613596-A Biomarkers for detecting and distinguishing invasive prostate cancer from inert forms and treatment of invasive prostate cancer 约翰霍普金斯大学 2024-09-06 CN disclosed
US-20240164377-A1 LOW VOLATILITY PROMOTING WATER CONDITIONING ADJUVANTS ADJUVANTS UNLIMITED LLC (US) 2024-05-23 US disclosed
CN-117571844-A Method for detecting organic acid in human body tricarboxylic acid cycle 凯莱谱科技股份有限公司 2024-02-20 CN disclosed
EP-4218773-A1 HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF Kyoto Prefectural Public University Corporation (JP) 2023-08-02 EP disclosed
CN-115267014-B Method for detecting organic acid in tricarboxylic acid cycle 杭州凯莱谱精准医疗检测技术有限公司 2023-05-26 CN disclosed
EP-3416658-B1 HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) 2023-03-22 EP disclosed
CN-115407065-A Diagnostic and therapeutic preparations for thrombocytopenic multiple myeloma 细胞生态海河实验室 2022-11-29 CN disclosed
CN-101793752-A Isocitric acid determination reagent (kit) and isocitric acid concentration determination method SUZHOU ANJ BIOTECH CO LTD 2010-08-04 CN disclosed
CN-101609020-A The method for measurement of concentration of isocitric acid measuring kit and isocitric acid SUZHOU ANJ BIOTECH CO LTD (CN) 2009-12-23 CN disclosed
CN-101609019-A The method for measurement of concentration of isocitric acid measuring kit and isocitric acid SUZHOU ANJ BIOTECH CO LTD (CN) 2009-12-23 CN disclosed
CN-101464284-A Isocitric acid measuring reagent kit and isocitric acid concentration determination method SUZHOU ANJ BIOTECH CO LTD (CN) 2009-06-24 CN disclosed
CN-101464308-A Isocitric acid measuring reagent kit and isocitric acid concentration determination method SUZHOU ANJ BIOTECH CO LTD (CN) 2009-06-24 CN disclosed
CN-101464283-A Isocitric acid measuring reagent kit and isocitric acid concentration determination method SUZHOU ANJ BIOTECH CO LTD (CN) 2009-06-24 CN disclosed
CN-101464282-A Isocitric acid measuring reagent kit and isocitric acid concentration determination method SUZHOU ANJ BIOTECH CO LTD (CN) 2009-06-24 CN disclosed
CN-101464281-A Isocitric acid measuring reagent kit and isocitric acid concentration determination method SUZHOU ANJ BIOTECH CO LTD (CN) 2009-06-24 CN disclosed
CN-101464285-A Isocitric acid measuring reagent kit and isocitric acid concentration determination method SUZHOU ANJ BIOTECH CO LTD (CN) 2009-06-24 CN disclosed
US-4629690-A COMPETITIVE PROTEIN BINDING USING A SECOND ENZYME RELATED TO THE FIRST BY THE PRODUCT OF ONE BEING THE SUBSTRATE OF THE OTHER SYNTEX (U.S.A.) INC. (US) 1986-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034177-A1 HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF EPCAM, CD44, SLC17A5 TDP1 4772/4885SMN1; SMN2 4697/4885SLC22A6 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.